NBIX vs VG · P/E 45, rev $2.36B vs P/E 11, rev $13.77B
Neurocrine Biosciences Inc (NBIX) versus Venture Global, Inc. (VG) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Venture Global, Inc. (VG) is a oil & gas midstream company listed on NYSE.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported VG revenue for 2025-12-31 was $13.77B. Net income was $2.73B. Revenue was up 176.9% from 2024-12-31 to 2025-12-31. VG currently screens at market cap $26.69B and trailing P/E 11.2.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. VG currently screens at market cap $26.69B and trailing P/E 11.2.
Not investment advice. Open the NBIX and VG stock pages for the full models.
Not investment advice.